Topic Editors

Prof. Dr. Shenglin Huang
1. Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai 200032, China
2. Shanghai Cancer Center, Fudan University, Shanghai 200032, China
Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
Dr. Jialei Wang
1. Department of Thoracic Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China
2. Institute of Thoracic Oncology, Fudan University, Shanghai 200032, China

Extracellular Vesicles in Cancer Diagnosis and Treatment

Abstract submission deadline
closed (20 May 2024)
Manuscript submission deadline
20 July 2024
Viewed by
7290

Topic Information

Dear Colleagues,

Extracellular vesicles (EVs) are specialized membranous, nanosized endocytic vesicles that are secreted by most cell types in the human body, including tumor cells. EVs contain key biomolecules such as RNA, DNA, proteins, and lipids, which are promising biomarkers for clinical applications in cancer management. This Topic aims to contribute original articles and reviews to the investigation and identification of EV-related biomarkers for cancer diagnosis and treatment.

Prof. Dr. Shenglin Huang
Dr. Linlin Guo
Dr. Jialei Wang
Topic Editors

Keywords

  • extracellular vesicles
  • cancer diagnosis
  • cancer treatment
  • mRNA
  • lncRNA
  • circRNA
  • protein
  • DNA
  • biomarker

Participating Journals

Journal Name Impact Factor CiteScore Launched Year First Decision (median) APC
Biomolecules
biomolecules
5.5 8.3 2011 16.9 Days CHF 2700 Submit
Cancers
cancers
5.2 7.4 2009 17.9 Days CHF 2900 Submit
Current Oncology
curroncol
2.6 2.6 1994 18 Days CHF 2200 Submit
Journal of Clinical Medicine
jcm
3.9 5.4 2012 17.9 Days CHF 2600 Submit
Onco
onco
- - 2021 18.3 Days CHF 1000 Submit

Preprints.org is a multidiscipline platform providing preprint service that is dedicated to sharing your research from the start and empowering your research journey.

MDPI Topics is cooperating with Preprints.org and has built a direct connection between MDPI journals and Preprints.org. Authors are encouraged to enjoy the benefits by posting a preprint at Preprints.org prior to publication:

  1. Immediately share your ideas ahead of publication and establish your research priority;
  2. Protect your idea from being stolen with this time-stamped preprint article;
  3. Enhance the exposure and impact of your research;
  4. Receive feedback from your peers in advance;
  5. Have it indexed in Web of Science (Preprint Citation Index), Google Scholar, Crossref, SHARE, PrePubMed, Scilit and Europe PMC.

Published Papers (3 papers)

Order results
Result details
Journals
Select all
Export citation of selected articles as:
13 pages, 5060 KiB  
Article
Fusion with ARRDC1 or CD63: A Strategy to Enhance p53 Loading into Extracellular Vesicles for Tumor Suppression
by Min Liu, Yu Zhang, Jianfeng He, Wanxi Liu, Zhexuan Li, Yiti Zhang, Ao Gu, Mingri Zhao, Mujun Liu and Xionghao Liu
Biomolecules 2024, 14(5), 591; https://doi.org/10.3390/biom14050591 - 16 May 2024
Viewed by 358
Abstract
Small extracellular vesicles (sEVs) have emerged as promising therapeutic agents and drug delivery vehicles. Targeted modification of sEVs and their contents using genetic modification strategies is one of the most popular methods. This study investigated the effects of p53 fusion with arrestin domain-containing [...] Read more.
Small extracellular vesicles (sEVs) have emerged as promising therapeutic agents and drug delivery vehicles. Targeted modification of sEVs and their contents using genetic modification strategies is one of the most popular methods. This study investigated the effects of p53 fusion with arrestin domain-containing protein 1 (ARRDC1) and CD63 on the generation of sEVs, p53 loading efficiency, and therapeutic efficacy. Overexpression of either ARRDC1–p53 (ARP) or CD63–p53 (CDP) significantly elevated p53 mRNA and protein levels. The incorporation of ARRDC1 and CD63 significantly enhanced HEK293T-sEV biogenesis, evidenced by significant increases in sEV-associated proteins TSG101 and LAMP1, resulting in a boost in sEV production. Importantly, fusion with ARRDC1 or CD63 substantially increased the efficiency of loading both p53 fusion proteins and its mRNA into sEVs. sEVs equipped with ARP or CDP significantly enhanced the enrichment of p53 fusion proteins and mRNA in p53-null H1299 cells, resulting in a marked increase in apoptosis and a reduction in cell proliferation, with ARP-sEVs demonstrating greater effectiveness than CDP-sEVs. These findings underscore the enhanced functionality of ARRDC1- and CD63-modified sEVs, emphasizing the potential of genetic modifications in sEV-based therapies for targeted cancer treatment. Full article
(This article belongs to the Topic Extracellular Vesicles in Cancer Diagnosis and Treatment)
Show Figures

Figure 1

22 pages, 1643 KiB  
Review
Plant-Derived Extracellular Vesicles and Their Exciting Potential as the Future of Next-Generation Drug Delivery
by Faisal A. Alzahrani, Mohammad Imran Khan, Nader Kameli, Elham Alsahafi and Yasir Mohamed Riza
Biomolecules 2023, 13(5), 839; https://doi.org/10.3390/biom13050839 - 15 May 2023
Cited by 16 | Viewed by 4334
Abstract
Plant cells release tiny membranous vesicles called extracellular vesicles (EVs), which are rich in lipids, proteins, nucleic acids, and pharmacologically active compounds. These plant-derived EVs (PDEVs) are safe and easily extractable and have been shown to have therapeutic effects against inflammation, cancer, bacteria, [...] Read more.
Plant cells release tiny membranous vesicles called extracellular vesicles (EVs), which are rich in lipids, proteins, nucleic acids, and pharmacologically active compounds. These plant-derived EVs (PDEVs) are safe and easily extractable and have been shown to have therapeutic effects against inflammation, cancer, bacteria, and aging. They have shown promise in preventing or treating colitis, cancer, alcoholic liver disease, and even COVID-19. PDEVs can also be used as natural carriers for small-molecule drugs and nucleic acids through various administration routes such as oral, transdermal, or injection. The unique advantages of PDEVs make them highly competitive in clinical applications and preventive healthcare products in the future. This review covers the latest methods for isolating and characterizing PDEVs, their applications in disease prevention and treatment, and their potential as a new drug carrier, with special attention to their commercial viability and toxicological profile, as the future of nanomedicine therapeutics. This review champions the formation of a new task force specializing in PDEVs to address a global need for rigor and standardization in PDEV research. Full article
(This article belongs to the Topic Extracellular Vesicles in Cancer Diagnosis and Treatment)
Show Figures

Figure 1

18 pages, 2599 KiB  
Review
Exosomal LncRNAs in Gastrointestinal Cancer: Biological Functions and Emerging Clinical Applications
by Yuntong Sun, Fengtian Sun, Jianhua Jin, Wenrong Xu and Hui Qian
Cancers 2023, 15(3), 959; https://doi.org/10.3390/cancers15030959 - 2 Feb 2023
Cited by 4 | Viewed by 1723
Abstract
Due to the lack of specific and effective biomarkers and therapeutic targets, the early diagnosis and treatment of gastrointestinal cancer remain unsatisfactory. As a type of nanosized vesicles derived from living cells, exosomes mediate cell-to-cell communication by transporting bioactive molecules, thus participating in [...] Read more.
Due to the lack of specific and effective biomarkers and therapeutic targets, the early diagnosis and treatment of gastrointestinal cancer remain unsatisfactory. As a type of nanosized vesicles derived from living cells, exosomes mediate cell-to-cell communication by transporting bioactive molecules, thus participating in the regulation of many pathophysiological processes. Recent evidence has revealed that several long non-coding RNAs (lncRNAs) are enriched in exosomes. Exosomes-mediated lncRNAs delivery is critically involved in various aspects of gastrointestinal cancer progression, such as tumor proliferation, metastasis, angiogenesis, stemness, immune microenvironment, and drug resistance. Exosomal lncRNAs represent promising candidates to act as the diagnosis biomarkers and anti-tumor targets. This review introduces the major characteristics of exosomes and lncRNAs and describes the biological functions of exosomal lncRNAs in gastrointestinal cancer development. The preclinical studies on using exosomal lncRNAs to monitor and treat gastrointestinal cancer are also discussed, and the opportunities and challenges for translating them into clinical practice are evaluated. Full article
(This article belongs to the Topic Extracellular Vesicles in Cancer Diagnosis and Treatment)
Show Figures

Figure 1

Back to TopTop